Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Se

Arcutis Biotherapeutics, Inc. (ARQT)

We couldn't retrieve the full text for this release. Read it on the company's site.